12:28 PM EDT, 08/08/2024 (MT Newswires) -- Kura Oncology ( KURA ) said Thursday that the US Food and Drug Administration has cleared the investigational new drug application for ziftomenib to treat advanced gastrointestinal stromal tumors, or GIST.

The company said it plans to start a phase 1 first-in-human trial of ziftomenib plus imatinib in patients with advanced GIST in early 2025.

Preclinical data show that combining ziftomenib with imatinib might make patients who are resistant to imatinib respond to it again and have lasting results, the company added.

Shares of Kura Oncology ( KURA ) rose more than 2% in recent trading.

Price: 18.98, Change: +0.41, Percent Change: +2.21